MMP9 and metabolic syndrome: Since the concentrations of MMP-2 and MMP-9 are higher in patients with the metabolic syndrome [27] and TIMP-1 is significantly higher in obese patients [26], we assumed that the higher concentrations of the analyzed markers are the consequence rather than the cause of cardiometabolic complications.